Budesonide Nasal Spray therapy

Phase 2Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Budesonide Nasal Spray therapy is one of 42 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Olfactory DysfunctionNot yet recruiting

Allergic RhinitisPreclinical

Active, not recruiting

Olfactory DysfunctionPhase 2

Not yet recruiting

Competition

Competitive Landscape

52 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Singulair

OOrganon and Co

Approved

13 2

Flovent

PParatek Pharmaceuticals Inc

Approved

12 3

Xyzal

CChattem

Approved

11 4

Alvesco

AAzurity Pharmaceuticals

Approved

8 5

Claritin

PPerrigo Company

Approved

6 6

Zyrtec

KKenvue Brands

Approved

5 7

Pulmicort

SSalix

Approved

5 8

Clarinex

OOrganon and Co

Approved

5 9

Qvar

SSchering-Plough

Approved

4 10

Allegra

CChattem

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Olfactory Dysfunction

NCT04918953

Clinical

Trials by Indication[1]

Olfactory Dysfunction1 trial

Factors Influencing the Prognosis of Olfactory Dysfunction After Upper Sensation

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04918953·90 enrolled

Allergic Rhinitis1 trial

The Use of Hydrogen Ion Water (Shan Shang Water) in the Treatment of Allergic Rhinitis

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06756243·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Budesonide Nasal Spray therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Budesonide Nasal Spray therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Budesonide Nasal Spray therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Budesonide Nasal Spray therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Olfactory Dysfunction1 trial

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News